Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

SPT Labtech, a global leader in life sciences automation solutions, today announced its inclusion in an Illumina partnership program to develop Illumina Qualified automated library prep methods, ...

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...